-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on NeoGenomics, Raises Price Target to $22

Benzinga·10/06/2026 11:12:58
语音播报
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $19 to $22.